MA48970B1 - Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate - Google Patents

Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Info

Publication number
MA48970B1
MA48970B1 MA48970A MA48970A MA48970B1 MA 48970 B1 MA48970 B1 MA 48970B1 MA 48970 A MA48970 A MA 48970A MA 48970 A MA48970 A MA 48970A MA 48970 B1 MA48970 B1 MA 48970B1
Authority
MA
Morocco
Prior art keywords
prostate diseases
copaifera oleoresin
copaifera
oleoresin
prostate
Prior art date
Application number
MA48970A
Other languages
English (en)
French (fr)
Other versions
MA48970A (fr
Inventor
Christel Fiorini-Puybaret
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of MA48970A publication Critical patent/MA48970A/fr
Publication of MA48970B1 publication Critical patent/MA48970B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA48970A 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate MA48970B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1752284A FR3063906B1 (fr) 2017-03-20 2017-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
EP18711130.7A EP3600370B1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
PCT/EP2018/057076 WO2018172380A1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Publications (2)

Publication Number Publication Date
MA48970A MA48970A (fr) 2021-03-31
MA48970B1 true MA48970B1 (fr) 2024-06-28

Family

ID=59153043

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48970A MA48970B1 (fr) 2017-03-20 2018-03-20 Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Country Status (14)

Country Link
US (1) US11311591B2 (https=)
EP (1) EP3600370B1 (https=)
JP (1) JP7305546B2 (https=)
KR (1) KR102686593B1 (https=)
CN (1) CN110494149A (https=)
AU (1) AU2018240405B2 (https=)
BR (1) BR112019018744B1 (https=)
CA (1) CA3056293A1 (https=)
ES (1) ES2979106T3 (https=)
FR (1) FR3063906B1 (https=)
MA (1) MA48970B1 (https=)
MX (1) MX2019011118A (https=)
PL (1) PL3600370T3 (https=)
WO (1) WO2018172380A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020089944A1 (en) * 2018-11-03 2020-05-07 Olene Life Sciences Private Limited Process for preparing an herbal extract and compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH698144B1 (fr) * 2003-09-24 2009-05-29 Bioxell Spa Analogue de la vitamine D3

Also Published As

Publication number Publication date
RU2019132832A3 (https=) 2021-06-11
MA48970A (fr) 2021-03-31
EP3600370B1 (fr) 2024-04-03
BR112019018744A2 (pt) 2020-04-07
FR3063906B1 (fr) 2025-12-12
JP2020511488A (ja) 2020-04-16
PL3600370T3 (pl) 2024-07-29
BR112019018744B1 (pt) 2023-02-23
KR102686593B1 (ko) 2024-07-18
KR20190126091A (ko) 2019-11-08
AU2018240405A1 (en) 2019-11-07
CA3056293A1 (fr) 2018-09-27
RU2019132832A (ru) 2021-04-21
EP3600370C0 (fr) 2024-04-03
EP3600370A1 (fr) 2020-02-05
FR3063906A1 (fr) 2018-09-21
ES2979106T3 (es) 2024-09-24
AU2018240405B2 (en) 2024-04-11
US20200093879A1 (en) 2020-03-26
WO2018172380A1 (fr) 2018-09-27
US11311591B2 (en) 2022-04-26
CN110494149A (zh) 2019-11-22
MX2019011118A (es) 2019-11-05
JP7305546B2 (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
JOP20210129A1 (ar) مثبطات apol1 وطرق استخدامها
EA202090655A1 (ru) Комбинированные терапевтические средства и их применение
MX2017013533A (es) Composiciones de limpieza personal concentradas.
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2019002960A (es) Oligonucleótidos modificados y métodos de uso.
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
MX2022000712A (es) Moduladores de nlrp3.
MX2017013534A (es) Composiciones concentradas para la limipieza personal y usos.
EA202192047A1 (ru) Соединения и их применение
SA521430519B1 (ar) مثبطات مسار تبادل إشارات التحزيز واستخدامها في علاج السرطانات
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
MA48970B1 (fr) Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate